DE602005014686D1 - Herstellung eines atorvastatin-zwischenprodukts - Google Patents

Herstellung eines atorvastatin-zwischenprodukts

Info

Publication number
DE602005014686D1
DE602005014686D1 DE602005014686T DE602005014686T DE602005014686D1 DE 602005014686 D1 DE602005014686 D1 DE 602005014686D1 DE 602005014686 T DE602005014686 T DE 602005014686T DE 602005014686 T DE602005014686 T DE 602005014686T DE 602005014686 D1 DE602005014686 D1 DE 602005014686D1
Authority
DE
Germany
Prior art keywords
diol
ester
atorvastatin
acid
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602005014686T
Other languages
English (en)
Inventor
Susan O'sullivan
John O'neill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Science and Technology Ireland Ltd
Original Assignee
Pfizer Science and Technology Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Science and Technology Ireland Ltd filed Critical Pfizer Science and Technology Ireland Ltd
Publication of DE602005014686D1 publication Critical patent/DE602005014686D1/de
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602005014686T 2005-09-09 2005-09-09 Herstellung eines atorvastatin-zwischenprodukts Expired - Fee Related DE602005014686D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IE2005/000094 WO2007029216A1 (en) 2005-09-09 2005-09-09 Preparation of an atorvastatin intermediate

Publications (1)

Publication Number Publication Date
DE602005014686D1 true DE602005014686D1 (de) 2009-07-09

Family

ID=36283782

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005014686T Expired - Fee Related DE602005014686D1 (de) 2005-09-09 2005-09-09 Herstellung eines atorvastatin-zwischenprodukts

Country Status (7)

Country Link
US (1) US20090221839A1 (de)
EP (1) EP1922315B1 (de)
JP (1) JP2009507821A (de)
AT (1) ATE432276T1 (de)
CA (1) CA2621506A1 (de)
DE (1) DE602005014686D1 (de)
WO (1) WO2007029216A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL366610A1 (en) 2001-07-06 2005-02-07 Teva Pharmaceutical Industries Ltd. Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
WO2009023260A2 (en) * 2007-08-15 2009-02-19 Teva Pharmaceutical Industries Ltd. An improved process for synthesis of pyrrole derivative, an intermediate for atorvastatin
KR100850558B1 (ko) 2008-01-02 2008-08-06 조동옥 아토르바스타틴의 효율적인 제조방법
KR100850850B1 (ko) 2008-01-25 2008-08-06 주식회사종근당 아토르바스타틴의 제조방법 및 이에 사용되는 중간체
JP5705580B2 (ja) * 2011-02-21 2015-04-22 公益財団法人微生物化学研究会 チオアミド化合物、チオアミド化合物の製造方法、［（４ｒ，６ｒ）−６−アミノエチル−１，３−ジオキサン−４−イル］アセテート誘導体の製造方法、及びアトルバスタチンの製造方法
CN111362856B (zh) * 2020-04-29 2023-08-18 福建海西新药创制股份有限公司 一种利用微反应装置生产阿托伐他汀钙的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) * 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) * 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) * 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) * 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) * 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
DE19635598A1 (de) * 1996-09-02 1998-03-05 Focke & Co Anlage zum Handhaben von insbesondere Zigaretten
KR100668575B1 (ko) * 1997-12-19 2007-01-17 워너-램버트 익스포트 리미티드 1,3-디올의 합성방법
KR100877165B1 (ko) * 2000-11-16 2009-01-07 테바 파마슈티컬 인더스트리즈 리미티드 수산화 칼슘을 이용한[Ｒ(Ｒ*,Ｒ*)]-2-(4-플루오로페닐)-β,δ-디하이드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카보닐]-1Ｈ-피롤-1-헵탄산 에스테르의 가수분해

Also Published As

Publication number Publication date
WO2007029216A1 (en) 2007-03-15
CA2621506A1 (en) 2007-03-15
EP1922315A1 (de) 2008-05-21
EP1922315B1 (de) 2009-05-27
ATE432276T1 (de) 2009-06-15
US20090221839A1 (en) 2009-09-03
JP2009507821A (ja) 2009-02-26

Similar Documents

Publication Publication Date Title
DE602005014686D1 (de) Herstellung eines atorvastatin-zwischenprodukts
UY30649A1 (es) Compuestos de biaril éter urea
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
EA201070345A1 (ru) Смесь производных фурфураля и 5-алкоксиметилфурфураля из сахаров и спиртов
ECSP088765A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
NZ591973A (en) Anti-viral compounds to treat hcv infection
DOP2009000201A (es) Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h, 4h, 6h)carbaldehido como inhibidores pkc
TW200640918A (en) Isoxazoline derivative and novel process for its preparation
EA200800303A1 (ru) Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами
MY159060A (en) Adducts of levulinic derivatives with epoxidized fatty acid esters and uses thereof
UA100367C2 (uk) Спосіб одержання мемантину і його гідрохлориду
WO2005094323A3 (en) Process for preparing a dipeptidyl peptidase iv inhibitor and intermediates employed therein
AR051373A1 (es) Procedimiento para la preparacion de analogos aciclicos de nucleotidos de fosfonatos
BRPI0519337A2 (pt) composto de pirazol heteroarilas éteis no tratamento de doenÇas mediadas pela tnf-alfa e il-1
WO2009127949A8 (en) 4- [3- (aryloxy) benzylidene] -3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
DE502006006960D1 (de) Verfahren zur Herstellung von Carbonsäureestern
BR112012019307A2 (pt) processo para produzir composições de etanol anidras
UA94579C2 (ru) Анетолдитиолтион и другие дитиолтионы для лечения состояний, связанных с дисфункцией нейротрансмисии моноамина
WO2008100651A3 (en) Preparation of darifenacin and its salts
Li et al. Structure–activity relationship studies of 1-(1′-hydroxyalkyl) rupestonic acid methyl esters against influenza viruses
BR112015011574A2 (pt) processo para produzir um composto
EA200801400A1 (ru) Новые производные индолизина, способ их получения и терапевтические композиции на их основе
ATE517086T1 (de) Verfahren zur synthese von 3-amino-1- arylpropylindolen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee